What exactly did Cowen do on March 09, 2026 for the BNTC analyst rating?

Cowen & Co. reiterated a **Buy** on Benitec Biopharma Inc. (BNTC) on March 09, 2026 at 12:44 PM, citing strong proof of concept to support Phase 3 prospects. No new price target was published in the note.

Does the Cowen note include a new BNTC price target?

No. The March 09, 2026 Cowen comment reiterated the Buy rating but did not provide a new BNTC price target in the published summary on StreetInsider. Investors should monitor full research reports for updates.

How should investors interpret the maintained Buy versus an upgrade or downgrade?

A maintained Buy signals continued analyst confidence without changing the conviction level. It suggests Cowen sees value tied to clinical outcomes rather than new information shifting the stance. Investors should still assess clinical and regulatory risks.

What does Meyka AI’s B+ grade mean for BNTC investors?

Meyka AI rates BNTC **B+**, reflecting comparison to S&P 500, sector performance, growth metrics, and analyst views. This grade guides relative assessment but is not financial advice, and it does not guarantee performance.

Analyst Ratings

Cowen Reiterates Buy on Benitec Biopharma (BNTC) March 2026

ByDanny Kontos March 10, 2026March 10, 2026

Cowen & Co. maintained a Buy on Benitec Biopharma Inc. (BNTC) on March 09, 2026 at 12:44 PM, citing a “strong POC to support Ph3 success.” The BNTC analyst rating note left the recommendation unchanged, and Cowen did not attach a new price target in the published comment. We view this reiteration as continued analyst confidence in the company’s clinical path and pipeline milestones. The market cap stands at $328,613,028, and the share reaction was modest, up 0.24% ($0.03) on the update. Meyka AI rates BNTC with a grade of B+.